Skip to main content
Top
Gepubliceerd in:

13-10-2016

Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials

Auteur: Krzysztof Adamowicz

Gepubliceerd in: Quality of Life Research | Uitgave 4/2017

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Introduction

The chief therapeutic goal in metastatic prostate cancer is prolongation of survival with good quality of life . Quality of life (health-related) is often used as an endpoint parameter in phase III trials in metastatic prostate cancer, but the value of using HRQOL in this context has not been assessed to date.

Methods

In order to evaluate the role of HRQOL assessment in contemporary phase III trials in prostate cancer, we searched the PubMed database to identify publications presenting the results of these trials on systemic therapies for prostate cancer published between January 2000 and December 2015. The analysis was separately presented in ten leading journals. We searched for companion papers reporting on QOL separately.

Results

We identified 84 studies which included a total of 57,193 patients in ten leading journals and 27 studies (7270 patients) in other journals. HRQOL parameters were described or mentioned in the main publication in 25 publications and four companions in total. There was no obvious trend in quality of life reported over two 8-year periods . The explicit statistical comparisons were reported in 22/25 cases (88 %), with significant difference in only 10/25 (40 %) studies and in eight cases (80 %) was conducive to the examined arm. There was no significant association between improvements in HRQOL and improvements in overall survival (OS) or any other primary endpoint in the analyzed studies. Only one study was found which presented the difference in quality of life with no difference in the primary endpoint.

Conclusions

HRQOL is an indicator of benefit during treatment of patients with metastatic prostate cancer, but it is unlikely that HRQOL results can help clinicians choose between treatments given that they are not correlated with changes in OS or at other primary endpoints.
Literatuur
1.
go back to reference Mould, R. (2008). Cancer statistics overview with special reference to prostate, colon and rectum, lung, breast and cervix uteri. Nowotwory Journal of Oncology, 58, 213–220. Mould, R. (2008). Cancer statistics overview with special reference to prostate, colon and rectum, lung, breast and cervix uteri. Nowotwory Journal of Oncology, 58, 213–220.
2.
go back to reference Wojciechowska, U., Didkowska, J., & Zatoński, W. (2012). Nowotwory złośliwe w Polsce. Warszawa: Centrum Onkologii Instytut. Wojciechowska, U., Didkowska, J., & Zatoński, W. (2012). Nowotwory złośliwe w Polsce. Warszawa: Centrum Onkologii Instytut.
3.
go back to reference American Cancer Society. (2004). Cancer facts and figures-2004 Atlanta. Atlanta: American Cancer Society. American Cancer Society. (2004). Cancer facts and figures-2004 Atlanta. Atlanta: American Cancer Society.
4.
go back to reference The World Health Organization Quality of Life assessment. (1995). (WHOQOL): Position paper from the World Health Organization. Social Science and Medicine, 41, 1403–1409.CrossRef The World Health Organization Quality of Life assessment. (1995). (WHOQOL): Position paper from the World Health Organization. Social Science and Medicine, 41, 1403–1409.CrossRef
5.
go back to reference Greenfield, S., & Nelson, E. C. (1992). Recent developments and future issues in the use of health status assessment measures in clinical settings. Medical Care, 30, 23–41.CrossRef Greenfield, S., & Nelson, E. C. (1992). Recent developments and future issues in the use of health status assessment measures in clinical settings. Medical Care, 30, 23–41.CrossRef
6.
go back to reference Michael, M., & Tannock, I. F. (1998). Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment. Canadian Medical Association Journal, 158, 1727–1734.PubMedPubMedCentral Michael, M., & Tannock, I. F. (1998). Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment. Canadian Medical Association Journal, 158, 1727–1734.PubMedPubMedCentral
7.
go back to reference Minasian, L. M., O’Mara, A. M., Reeve, B. B., et al. (2007). Health-related quality of life and symptom management research sponsored by the National Cancer Institute. Journal of Clinical Oncology, 25, 5128–5132.CrossRefPubMed Minasian, L. M., O’Mara, A. M., Reeve, B. B., et al. (2007). Health-related quality of life and symptom management research sponsored by the National Cancer Institute. Journal of Clinical Oncology, 25, 5128–5132.CrossRefPubMed
8.
go back to reference Crook, J. M., O’Callaghan, C. J., Duncan, G., et al. (2012). Intermittent androgen suppression for rising PSA level after radiotherapy. New England Journal of Medicine, 367, 895–903.CrossRefPubMedPubMedCentral Crook, J. M., O’Callaghan, C. J., Duncan, G., et al. (2012). Intermittent androgen suppression for rising PSA level after radiotherapy. New England Journal of Medicine, 367, 895–903.CrossRefPubMedPubMedCentral
9.
go back to reference Scher, H. I., Fizazi, K., Saad, F., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine, 367, 1187–1197.CrossRefPubMed Scher, H. I., Fizazi, K., Saad, F., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine, 367, 1187–1197.CrossRefPubMed
10.
go back to reference Tannock, I. F., de Wit, R., Berry, W. R., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine, 351, 1502–1512.CrossRefPubMed Tannock, I. F., de Wit, R., Berry, W. R., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine, 351, 1502–1512.CrossRefPubMed
11.
go back to reference Loriot, Y., Miller, K., Sternberg, C. N., et al. (2015). Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): Results from a randomised, phase 3 trial. Lancet Oncology, 16, 509–521.CrossRefPubMed Loriot, Y., Miller, K., Sternberg, C. N., et al. (2015). Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): Results from a randomised, phase 3 trial. Lancet Oncology, 16, 509–521.CrossRefPubMed
12.
go back to reference Basch, E., Autio, K., Ryan, C. J., et al. (2013). Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: Patient-reported outcome results of a randomised phase 3 trial. Lancet Oncology, 14, 1193–1199.CrossRefPubMed Basch, E., Autio, K., Ryan, C. J., et al. (2013). Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: Patient-reported outcome results of a randomised phase 3 trial. Lancet Oncology, 14, 1193–1199.CrossRefPubMed
13.
go back to reference Fosså, S. D., Slee, P. H., Brausi, M., et al. (2001). Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: A phase III study of the European organization for research and treatment of cancer genitourinary group. Journal of Clinical Oncology, 19, 62–71.CrossRefPubMed Fosså, S. D., Slee, P. H., Brausi, M., et al. (2001). Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: A phase III study of the European organization for research and treatment of cancer genitourinary group. Journal of Clinical Oncology, 19, 62–71.CrossRefPubMed
14.
go back to reference Harland, S., Staffurth, J., Molina, A., et al. (2013). Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. European Journal of Cancer, 49, 3648–3657.CrossRefPubMed Harland, S., Staffurth, J., Molina, A., et al. (2013). Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. European Journal of Cancer, 49, 3648–3657.CrossRefPubMed
15.
go back to reference Cella, D., Ivanescu, C., Holmstrom, S., Bui, C. N., Spalding, J., & Fizazi, K. (2015). Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: Additional analyses from the AFFIRM randomized clinical trial. Annals of Oncology, 26, 179–185.CrossRefPubMed Cella, D., Ivanescu, C., Holmstrom, S., Bui, C. N., Spalding, J., & Fizazi, K. (2015). Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: Additional analyses from the AFFIRM randomized clinical trial. Annals of Oncology, 26, 179–185.CrossRefPubMed
16.
go back to reference Nelson, J. B., Fizazi, K., Miller, K., et al. (2012). Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer, 118, 5709–5718.CrossRefPubMed Nelson, J. B., Fizazi, K., Miller, K., et al. (2012). Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer, 118, 5709–5718.CrossRefPubMed
17.
go back to reference Abratt, R. P., Brune, D., Dimopoulos, M. A., et al. (2004). Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Annals of Oncology, 15, 1613–1621.CrossRefPubMed Abratt, R. P., Brune, D., Dimopoulos, M. A., et al. (2004). Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Annals of Oncology, 15, 1613–1621.CrossRefPubMed
18.
go back to reference Shamash, J., Powles, T., Sarker, S. J., et al. (2011). A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: Immediate vs deferred Diethylstilbestrol. British Journal of Cancer, 104, 620–628.CrossRefPubMedPubMedCentral Shamash, J., Powles, T., Sarker, S. J., et al. (2011). A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: Immediate vs deferred Diethylstilbestrol. British Journal of Cancer, 104, 620–628.CrossRefPubMedPubMedCentral
19.
go back to reference Fizazi, K., Lesaunier, F., Delva, R., et al. (2012). A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial. European Journal of Cancer, 48, 209–217.CrossRefPubMed Fizazi, K., Lesaunier, F., Delva, R., et al. (2012). A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial. European Journal of Cancer, 48, 209–217.CrossRefPubMed
20.
go back to reference Small, E. J., Meyer, M., Marshall, M. E., et al. (2000). Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. Journal of Clinical Oncology, 18, 1440–1450.CrossRefPubMed Small, E. J., Meyer, M., Marshall, M. E., et al. (2000). Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. Journal of Clinical Oncology, 18, 1440–1450.CrossRefPubMed
21.
go back to reference Fizazi, K., Higano, C. S., Nelson, J. B., et al. (2013). Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 31, 1740–1747.CrossRefPubMed Fizazi, K., Higano, C. S., Nelson, J. B., et al. (2013). Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 31, 1740–1747.CrossRefPubMed
22.
go back to reference Vitolins, M. Z., Griffin, L., Tomlinson, W. V., et al. (2013). Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer. Journal of Clinical Oncology, 31, 4092–4098.CrossRefPubMedPubMedCentral Vitolins, M. Z., Griffin, L., Tomlinson, W. V., et al. (2013). Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer. Journal of Clinical Oncology, 31, 4092–4098.CrossRefPubMedPubMedCentral
23.
go back to reference Brundage, M., Sydes, M. R., Parulekar, W. R., et al. (2015). Impact of radiotherapy when added to androgen-deprivation therapy for locally advanced prostate cancer: Long-term quality-of-life outcomes from the NCIC CTG PR3/MRC PR07 randomized trial. Journal of Clinical Oncology, 33, 2151–2157.CrossRefPubMedPubMedCentral Brundage, M., Sydes, M. R., Parulekar, W. R., et al. (2015). Impact of radiotherapy when added to androgen-deprivation therapy for locally advanced prostate cancer: Long-term quality-of-life outcomes from the NCIC CTG PR3/MRC PR07 randomized trial. Journal of Clinical Oncology, 33, 2151–2157.CrossRefPubMedPubMedCentral
24.
go back to reference Ernst, D. S., Tannock, I. F., Winquist, E. W., et al. (2003). Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. Journal of Clinical Oncology, 21, 3335–3342.CrossRefPubMed Ernst, D. S., Tannock, I. F., Winquist, E. W., et al. (2003). Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. Journal of Clinical Oncology, 21, 3335–3342.CrossRefPubMed
25.
go back to reference Saad, F., Gleason, D. M., Murray, R., et al. (2002). Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 94, 1458–1468.CrossRefPubMed Saad, F., Gleason, D. M., Murray, R., et al. (2002). Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 94, 1458–1468.CrossRefPubMed
26.
go back to reference Fransson, P., Lund, J. A., Damber, J. E., et al. (2009). Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncology, 10, 370–380.CrossRefPubMed Fransson, P., Lund, J. A., Damber, J. E., et al. (2009). Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncology, 10, 370–380.CrossRefPubMed
27.
go back to reference Denham, J. W., Wilcox, C., Joseph, D., et al. (2012). Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncology, 13, 1260–1270.CrossRefPubMed Denham, J. W., Wilcox, C., Joseph, D., et al. (2012). Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncology, 13, 1260–1270.CrossRefPubMed
28.
go back to reference Goodwin, P. J., Black, J. T., Bordeleau, L. J., & Ganz, P. A. (2003). Health-related quality-of-life measurement in randomized clinical trials in breast cancer–taking stock. Journal of the National Cancer Institute, 95, 263–281.CrossRefPubMed Goodwin, P. J., Black, J. T., Bordeleau, L. J., & Ganz, P. A. (2003). Health-related quality-of-life measurement in randomized clinical trials in breast cancer–taking stock. Journal of the National Cancer Institute, 95, 263–281.CrossRefPubMed
29.
go back to reference Simes, R. J., Greatorex, V., & Gebski, V. J. (1998). Practical approaches to minimize problems with missing quality of life data. Statistics in Medicine, 17, 725–737.CrossRefPubMed Simes, R. J., Greatorex, V., & Gebski, V. J. (1998). Practical approaches to minimize problems with missing quality of life data. Statistics in Medicine, 17, 725–737.CrossRefPubMed
30.
go back to reference Aaronson, N. K., Ahmedzai, S., Berman, B., et al. (1993). The Eurpean Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365–376.CrossRefPubMed Aaronson, N. K., Ahmedzai, S., Berman, B., et al. (1993). The Eurpean Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365–376.CrossRefPubMed
31.
go back to reference Fayers, P., & Bottomley, A. (2002). Quality of life research within the EORTC—the EORTC QLQ-C30. European Journal of Cancer, 38, 125–133.CrossRef Fayers, P., & Bottomley, A. (2002). Quality of life research within the EORTC—the EORTC QLQ-C30. European Journal of Cancer, 38, 125–133.CrossRef
32.
go back to reference Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et al. (1993). The functional assessment of cancer therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11, 570–579.CrossRefPubMed Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et al. (1993). The functional assessment of cancer therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11, 570–579.CrossRefPubMed
33.
go back to reference Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997). Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology, 50(6), 920–928.CrossRefPubMed Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997). Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology, 50(6), 920–928.CrossRefPubMed
34.
go back to reference King, M., Bell, M. L., Costa, D., Butow, P., & Oh, B. (2014). The quality of life questionnaire core 30 (QLQ-C30) and functional assessment of cancer-general (FACT-G) differ in responsiveness, relative efficiency, and therefore required sample size. Journal of Clinical Epidemiology, 67, 100–107.CrossRefPubMed King, M., Bell, M. L., Costa, D., Butow, P., & Oh, B. (2014). The quality of life questionnaire core 30 (QLQ-C30) and functional assessment of cancer-general (FACT-G) differ in responsiveness, relative efficiency, and therefore required sample size. Journal of Clinical Epidemiology, 67, 100–107.CrossRefPubMed
35.
go back to reference Bottomley, A., & Aaronson, N. K. (2007). International perspective on health-related quality of-life research in cancer clinical trials: The European Organisation for Research and Treatment of Cancer experience. Journal of Clinical Oncology, 25, 5082–5086.CrossRefPubMed Bottomley, A., & Aaronson, N. K. (2007). International perspective on health-related quality of-life research in cancer clinical trials: The European Organisation for Research and Treatment of Cancer experience. Journal of Clinical Oncology, 25, 5082–5086.CrossRefPubMed
36.
go back to reference Adamowicz, K., Jassem, J., Katz, A., & Saad, E. D. (2012). Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials. Cancer Treatment Reviews, 38, 554–558.CrossRefPubMed Adamowicz, K., Jassem, J., Katz, A., & Saad, E. D. (2012). Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials. Cancer Treatment Reviews, 38, 554–558.CrossRefPubMed
37.
go back to reference Saad, E. D., Adamowicz, K., Katz, A., & Jassem, J. (2012). Assessment of quality of life in advanced non-small-cell lung cancer: An overview of recent randomized trials. Cancer Treatment Reviews, 38, 807–814.CrossRefPubMed Saad, E. D., Adamowicz, K., Katz, A., & Jassem, J. (2012). Assessment of quality of life in advanced non-small-cell lung cancer: An overview of recent randomized trials. Cancer Treatment Reviews, 38, 807–814.CrossRefPubMed
38.
go back to reference Montazeri, A. (2008). Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007. Journal of Experimental and Clinical Cancer Research, 27, 32.CrossRefPubMedPubMedCentral Montazeri, A. (2008). Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007. Journal of Experimental and Clinical Cancer Research, 27, 32.CrossRefPubMedPubMedCentral
39.
go back to reference Dancey, J., Zee, B., Osoba, D., et al. (1997). Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Quality of Life Research, 6, 151–158.CrossRefPubMed Dancey, J., Zee, B., Osoba, D., et al. (1997). Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Quality of Life Research, 6, 151–158.CrossRefPubMed
40.
go back to reference Montazeri, A. (2009). Quality of life data as prognostic indicators of survival in cancer patients: An overview of the literature from 1982 to 2008. Health Qual Life Outcomes, 7, 102.CrossRefPubMedPubMedCentral Montazeri, A. (2009). Quality of life data as prognostic indicators of survival in cancer patients: An overview of the literature from 1982 to 2008. Health Qual Life Outcomes, 7, 102.CrossRefPubMedPubMedCentral
41.
go back to reference Van Steen, K., Curran, D., Kramer, J., et al. (2002). Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: Identification and impact on model selection. Statistics in Medicine, 21, 3865–3884.CrossRefPubMed Van Steen, K., Curran, D., Kramer, J., et al. (2002). Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: Identification and impact on model selection. Statistics in Medicine, 21, 3865–3884.CrossRefPubMed
Metagegevens
Titel
Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials
Auteur
Krzysztof Adamowicz
Publicatiedatum
13-10-2016
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 4/2017
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-016-1429-9

Andere artikelen Uitgave 4/2017

Quality of Life Research 4/2017 Naar de uitgave